MRK catalysts
Catalysts and events linked to MRK, newest first.
MRK stock catalysts and risks
Latest published review: 2026-10-21
| Development | Transmission channel | Evidence | Condition to watch |
|---|---|---|---|
| Moderna reported positive phase 3 cancer vaccine results 2026-10-21 · Up | combination-therapy optionality via Keytruda regimen exposure | The source says intismeran autogene was paired with Merck's Keytruda for melanoma treatment. | Not recorded |
| Merck Faces 12.8% EPS Contraction Forecast Ahead of October 29 Print 2026-10-01 · Mixed | quarterly earnings multiple compression on projected 12.79% EPS drop | Q3 2026 EPS consensus is $2.25 versus prior-year period. | Not recorded |
| Merck Sets Q3 2026 Earnings Release for October 29 Amid Pipeline Scrutiny 2026-10-01 · Mixed | oncology product sales trajectory and R&D pipeline replacement | Merck Q3 2026 earnings slated for October 29 with projected EPS of $2.25 on $17.52B revenue. | Not recorded |
| Merck declines 2.66% ahead of October 29 Q3 earnings as consensus models 12.8% EPS drop 2026-10-01 · Down | net margin contraction via higher operational R&D spending | Stock declined 2.66% to $145.31 with Q3 EPS projected to fall 12.79% YoY to $2.25. | Not recorded |
| Moderna and Merck Report Positive Phase III Trial Results for mRNA Cancer Therapy 2026-09-16 · Up | combination regimen pipeline expansion in immuno-oncology | Merck co-developed intismeran autogene with Moderna with positive Phase III outcomes. | Not recorded |
Do these developments change your position?
Review MRK alongside your other holdings and identify which decision deserves attention first.
Review your initial audit before choosing ongoing portfolio scanning at $79/month.
DateCardAvg 5d
- 2026-10-21Moderna reported positive phase 3 cancer vaccine resultsMRK MRNA
- 2026-10-21Moderna reported positive phase 3 cancer vaccine resultsMRK MRNA
- 2026-10-01Merck declines 2.66% ahead of October 29 Q3 earnings as consensus models 12.8% EPS dropMRK
- 2026-10-01Merck Sets Q3 2026 Earnings Release for October 29 Amid Pipeline ScrutinyMRK
- 2026-10-01Merck Faces 12.8% EPS Contraction Forecast Ahead of October 29 PrintMRK XLV+1.18%
- 2026-10-01Merck declines 2.66% ahead of October 29 Q3 earnings as consensus models 12.8% EPS dropMRK
- 2026-09-16Moderna and Merck Report Positive Phase III Trial Results for mRNA Cancer TherapyMRK
- 2026-09-16Moderna and Merck Report Positive Phase III Trial Results for mRNA Cancer TherapyMRK MRNA
- 2026-09-16Moderna and Merck Report Positive Phase III Trial Results for mRNA Cancer TherapyMRK MRNA
- 2026-06-25Global HPV Vaccine Market Projected to Reach $18.4B by 2034GSK MRK
- 2026-05-26Merck, Verizon, Equinix Recommended as Long-Term Dividend StocksEQIX MRK VZ
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.